Meglumine gadoterate: a new safe radiocontrast medium for endoscopic retrograde cholangiopancreatography?

Détails

ID Serval
serval:BIB_9A6A3D2847DC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Meglumine gadoterate: a new safe radiocontrast medium for endoscopic retrograde cholangiopancreatography?
Périodique
Digestion
Auteur⸱e⸱s
Dorta  G., Uske  A., Blum  A. L.
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
1997
Peer-reviewed
Oui
Volume
58
Numéro
3
Pages
289-92
Notes
Research Support, Non-U.S. Gov't
Dorta, G
Uske, A
Blum, A L
Switzerland
Digestion
Digestion. 1997;58(3):289-92.
Résumé
The radiocontrast substance meglumine gadoterate (MG) is used in magnetic resonance imaging. It is characterized by its low rate of adverse drug reactions. In an open study we tested whether MG is useful in endoscopic retrograde cholangiopancreatography. The patients received in sequence MG and ioxotalamate. MG, in contrast to ioxotalamate, failed to visualize the proximal pancreatic and peripheral intrahepatic ducts. Thus, MG is not useful in routine endoscopic retrograde cholangiopancreatography. However, in patients with a history of severe allergic reactions to conventional contrast media, MG may be recommended when pathological findings of the extrahepatic bile duct or the area of the pancreatic head are suspected.
Mots-clé
Adolescent Adult Aged Aged, 80 and over Biliary Tract/*radiography Cholangiopancreatography, Endoscopic Retrograde/*methods *Contrast Media Female Gadolinium/adverse effects/*diagnostic use Gallstones/radiography Humans Iothalamic Acid/adverse effects/analogs & derivatives/diagnostic use Male Meglumine/adverse effects/*diagnostic use Middle Aged Organometallic Compounds/adverse effects/*diagnostic use Pancreatic Ducts/*radiography Pancreatitis/radiography Radiographic Image Enhancement
Pubmed
Web of science
Création de la notice
10/04/2008 17:52
Dernière modification de la notice
20/08/2019 16:01
Données d'usage